Create your page here
Latest News for: Pharmaceutical sources
Edit
Hemogenyx Pharmaceuticals PLC Announces Admission of New Ordinary Shares and New ISIN
ACCESSWIRE 11 Dec 2024
Hemogenyx Pharmaceuticals plc ... Hemogenyx Pharmaceuticals plc ... About Hemogenyx Pharmaceuticals plc. Hemogenyx Pharmaceuticals is a publicly traded company (LSE ... SOURCE. Hemogenyx Pharmaceuticals PLC ....
Edit
NLS Pharmaceutics CEO Issues Letter to Shareholders
ACCESSWIRE 11 Dec 2024
ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd ... About NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd ... You may obtain free copies of these documents from NLS using the sources indicated above ... SOURCE. NLS Pharmaceutics AG ... ....
Edit
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Pharmiweb 10 Dec 2024
MIAMI, FL, December 10, 2024 (Newswire.com) - MIRA Pharmaceuticals, Inc ... Proof-of-concept results are anticipated by year-end 2025, marking a transformative year as MIRA transitions into a clinical-stage pharmaceutical company ... SOURCE ... Original Source.
Edit
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND ...
ACCESSWIRE 10 Dec 2024
MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc ... Proof-of-concept results are anticipated by year-end 2025, marking a transformative year as MIRA transitions into a clinical-stage pharmaceutical company ... SOURCE.
Edit
Hemogenyx Pharmaceuticals PLC Announces Site Initiation Visit Completed
ACCESSWIRE 09 Dec 2024
Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1 ... Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented. ... Hemogenyx Pharmaceuticals plc.
Edit
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
ACCESSWIRE 09 Dec 2024
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp ... Tonix Pharmaceuticals Holding Corp ... for more information on Tonix Pharmaceuticals. ... Tonix Pharmaceuticals.
Edit
De-oiled Lecithin Market Trends and Forecasts: A Comprehensive Overview for 2024 and Beyond
GetNews 09 Dec 2024
Edit
Charles R. Scheper, Chairman of Bexion Pharmaceuticals Board, Named Great Living Cincinnatian
Knoxville Daily Sun 07 Dec 2024
6, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a ... About Bexion Pharmaceuticals ... Bexion Pharmaceuticals ... SOURCE Bexion Pharmaceuticals, Inc.
Edit
Fentanyl found inside dolphins in Gulf of Mexico: ‘We think this is a longstanding problem’
New York Post 06 Dec 2024
Edit
Gluco Pure Blood Drops: The All-Natural Way to Support Blood Sugar and Heart Health
Maple Valley Reporter 06 Dec 2024
Edit
Saudi Firm Halts Acquisition of Osmopharm Stake
The Arabian Post 05 Dec 2024
SPIMACO, one of Saudi Arabia’s prominent pharmaceutical companies, has decided to cancel its agreement to acquire a majority stake in the pharmaceutical manufacturer Osmopharm ... pharmaceutical market.
Edit
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
ACCESSWIRE 05 Dec 2024
Sonoma Pharmaceuticals, Inc ... About Sonoma Pharmaceuticals, Inc ... Sonoma Pharmaceuticals™, Microcyn60®, Epicyn® and Pediacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc ... Sonoma Pharmaceuticals, Inc ... SOURCE.
Edit
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
ACCESSWIRE 05 Dec 2024
For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders ... SOURCE.
Edit
Investment fund seeks lawsuit against board of ‘benikoji’ maker
Asahi News 04 Dec 2024
A Hong Kong-based investment fund is demanding four auditors of Kobayashi Pharmaceutical Co. sue current and former board members for damages caused by the health scare over its red yeast supplements, sources said.
- 1
- 2
- Next page »